Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Northover AM | Modification by some antagonists of the shape changes of venous endothelial cells in response to inflammatory agents in vitro. | 1990 | Agents Actions | pmid:2111079 |
Trebien HA and Calixto JB | Pharmacological evaluation of rat paw oedema induced by Bothrops jararaca venom. | 1989 | Agents Actions | pmid:2660497 |
Bekemeier H and Sänze JU | Vasodepression ex vivo after administration of inflammatory mediators in vivo in the rat. | 1989 | Agents Actions | pmid:2476918 |
Sanchez Crespo M and Nieto ML | Modulation of PAF biosynthesis in human polymorphonuclear leukocytes. The role of phorbol esters and protein kinases. | 1989 | Agents Actions | pmid:2711927 |
Zijlstra FJ et al. | The effects of PAF-acether and FMLP on eicosanoid production in guinea pig alveolar macrophages. | 1989 | Agents Actions | pmid:2711928 |
Nieminen MM et al. | Body temperature modulates the effect of platelet-activating factor (PAF) on airways responsiveness in the rabbit. | 1991 | Agents Actions | pmid:1862740 |
Carlson RP et al. | Pharmacologic modulation of PAF-induced mortality in mice. | 1987 | Agents Actions | pmid:3120513 |
Pirotzky E et al. | Vascular permeability induced by Paf-acether (platelet-activating factor) in the isolated perfused rat kidney. | 1985 | Agents Actions | pmid:4003192 |
Page CP et al. | Platelet activating factor (Paf-acether) may account for late-onset reactions to allergen inhalation. | 1985 | Agents Actions | pmid:4003195 |
Page CP et al. | Suppression of Paf-acether responses: an anti-inflammatory effect of anti-asthma drugs. | 1985 | Agents Actions | pmid:4003196 |
Spicer BA et al. | An investigation of the involvement of platelet activating factor in the non-histamine immediate hypersensitivity reaction in the rat peritoneal cavity. | 1985 | Agents Actions | pmid:4003197 |
Boughton-Smith NK et al. | Actions of nitric oxide on the acute gastrointestinal damage induced by PAF in the rat. | 1992 | Agents Actions | pmid:1279960 |
Canale P et al. | TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock. | 1994 | Agents Actions | pmid:7879698 |
Denburg JA et al. | Platelet activating factor: regulation by mast cells and aspirin. | 1984 | Agents Actions | pmid:6711391 |
Vargaftig BB | Platelet-activating factor (PAF-acether) | 1982 | Agents Actions | pmid:7164939 |
Bette P and Bienvenue A | Exchange of a spin-labeled analog of PAF-acether between micelles, serum albumin and model membranes. | 1982 | Agents Actions | pmid:7164940 |
Lartigue-Mattei C et al. | Pharmacokinetic study of PAF-acether. Preliminary results after the intravenous administration of a 3H-labelled product to the rabbit. | 1982 | Agents Actions | pmid:7164941 |
Morgat JL et al. | Radio-labelling of 1-O-alkyl, 2-O-acetyl, sn-glycero-3-phosphorylcholine, 1-O-(9,10-di3H)-octadecyl PAF-acether. | 1982 | Agents Actions | pmid:7164942 |
Convert O et al. | 1H NMR of PAF-acether: influence of solvent on its structure. | 1982 | Agents Actions | pmid:7164943 |
Borrel MC et al. | Additional techniques for the total synthesis of PAF-acether. | 1982 | Agents Actions | pmid:7164944 |